INSIGHTEC, founded in 1999, develops and distributes the Exablate platform which provides non-invasive treatments for a variety of oncology and gynecology indications. The Exablate platform uses revolutionary MRgFUS technology which combines high intensity focused ultrasound guided by Magnetic Resonance Imaging (MRI). Focused ultrasound waves, guided by magnetic resonance imaging are used to safely ablate targeted tissue, ensuring a high rate of effectiveness with minimal side effects. INSIGHTEC is continuously investing and expanding its current and investigational applications, ranging from functional neurosurgery to oncology and gynecology. With over 13,000 Exablate treatments to date, MRgFUS technology is embraced by world renowned physicians in more than 120 medical facilities. The company has received numerous innovation awards - among them are The Wall Street Journal and TIME magazine. INSIGHTEC is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors.
